U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Zn
Molecular Weight 65.409
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of ZINC CATION

SMILES

[Zn++]

InChI

InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N
InChI=1S/Zn/q+2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
[Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections].
2005
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
[Reduced thymulin production during occupational exposure to lead].
2005 Jan-Mar
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Rats: The dose of zinc hydroxide administered to each rat was 85 mg/kg and represented 40% of the recommended daily allowance of a male adult human. This dose was administered in water solution at a final volume of 1 mL per rat.
Route of Administration: Oral
In Vitro Use Guide
Zinc hydroxide (1 mM) stimulates superoxide production by rat alveolar macrophages, as determined by CLA-dependent chemiluminescence.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:13:53 UTC 2023
Edited
by admin
on Wed Jul 05 23:13:53 UTC 2023
Record UNII
13S1S8SF37
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CATION
Common Name English
ZINC ION
Common Name English
ZINC(II)
Systematic Name English
ZINC ION(2+)
Common Name English
ZINC(2+)
Systematic Name English
ZINC, ION (ZN2+)
Common Name English
Classification Tree Code System Code
NDF-RT N0000175530
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
WHO-ATC D09AB01
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
NCI_THESAURUS C68295
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
NCI_THESAURUS C597
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
DSLD 137 (Number of products:9660)
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
Code System Code Type Description
FDA UNII
13S1S8SF37
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
DRUG BANK
DB14532
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
NDF-RT
N0000175529
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY Decreased Copper Ion Absorption [PE]
PUBCHEM
32051
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
DAILYMED
13S1S8SF37
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID40920495
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
RXCUI
1546264
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY RxNorm
CHEBI
29105
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
NCI_THESAURUS
C68296
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
CHEBI
27365
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
CAS
23713-49-7
Created by admin on Wed Jul 05 23:13:54 UTC 2023 , Edited by admin on Wed Jul 05 23:13:54 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
LIGAND->TARGET
Scientific Literature
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY